thalidomide has been researched along with Opportunistic Infections in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Opportunistic Infections: An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We present a case of coinfection with disseminated HSV and VZV infection in a patient taking thalidomide for relapsed multiple myeloma." | 7.71 | Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. ( Curley, MJ; Hassoun, PM; Hussein, SA, 2002) |
| "Newly diagnosed patients with multiple myeloma (MM) (n=122) aged greater than 55 yr, not eligible for transplantation were randomized to receive 8 cycles of M (9 mg/m(2) /d) and P (60 mg/m(2) /d) for 4d every 6 wk (n=62) or MP and thalidomide (100 mg/d) continuously (n=60)." | 6.76 | Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. ( Ali, R; Aydogdu, I; Beksac, M; Firatli-Tuglular, T; Goker, H; Gulbas, Z; Haznedar, R; Karakus, S; Kaya, E; Kaygusuz, I; Konuk, N; Ozdogu, H; Ozet, G; Sucak, G; Undar, L, 2011) |
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 6.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| " We present a case of coinfection with disseminated HSV and VZV infection in a patient taking thalidomide for relapsed multiple myeloma." | 3.71 | Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. ( Curley, MJ; Hassoun, PM; Hussein, SA, 2002) |
| "Newly diagnosed patients with multiple myeloma (MM) (n=122) aged greater than 55 yr, not eligible for transplantation were randomized to receive 8 cycles of M (9 mg/m(2) /d) and P (60 mg/m(2) /d) for 4d every 6 wk (n=62) or MP and thalidomide (100 mg/d) continuously (n=60)." | 2.76 | Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. ( Ali, R; Aydogdu, I; Beksac, M; Firatli-Tuglular, T; Goker, H; Gulbas, Z; Haznedar, R; Karakus, S; Kaya, E; Kaygusuz, I; Konuk, N; Ozdogu, H; Ozet, G; Sucak, G; Undar, L, 2011) |
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 2.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| "Lenalidomide-based therapy was associated with a significant increase in risk of serious infection in patients treated compared with conventional therapy (RR = 2." | 2.58 | Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. ( Chen, M; Mao, B; Wang, X; Xu, C; Zhang, X; Zhao, Y, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Armesto, S | 1 |
| González Vela, C | 1 |
| González López, MA | 1 |
| Chen, M | 1 |
| Zhao, Y | 1 |
| Xu, C | 1 |
| Wang, X | 1 |
| Zhang, X | 1 |
| Mao, B | 1 |
| Beksac, M | 1 |
| Haznedar, R | 1 |
| Firatli-Tuglular, T | 1 |
| Ozdogu, H | 1 |
| Aydogdu, I | 1 |
| Konuk, N | 1 |
| Sucak, G | 1 |
| Kaygusuz, I | 1 |
| Karakus, S | 1 |
| Kaya, E | 1 |
| Ali, R | 1 |
| Gulbas, Z | 1 |
| Ozet, G | 1 |
| Goker, H | 1 |
| Undar, L | 1 |
| Offidani, M | 1 |
| Corvatta, L | 1 |
| Polloni, C | 1 |
| Gentili, S | 1 |
| Brioni, A | 1 |
| Visani, G | 1 |
| Galieni, P | 1 |
| Brunori, M | 1 |
| Alesiani, F | 1 |
| Catarini, M | 1 |
| Centurioni, R | 1 |
| Samori, A | 1 |
| Blasi, N | 1 |
| Ferranti, M | 1 |
| Fraticelli, P | 1 |
| Mele, A | 1 |
| Rizzi, R | 1 |
| Larocca, F | 1 |
| Leoni, P | 1 |
| Kropff, MH | 1 |
| Lang, N | 1 |
| Bisping, G | 1 |
| Dominé, N | 1 |
| Innig, G | 1 |
| Hentrich, M | 1 |
| Mitterer, M | 1 |
| Südhoff, T | 1 |
| Fenk, R | 1 |
| Straka, C | 1 |
| Heinecke, A | 1 |
| Koch, OM | 1 |
| Ostermann, H | 1 |
| Berdel, WE | 1 |
| Kienast, J | 1 |
| Curley, MJ | 1 |
| Hussein, SA | 1 |
| Hassoun, PM | 1 |
| Georghiou, PR | 1 |
| Allworth, AM | 1 |
| Bouza, E | 1 |
| Muñoz, P | 1 |
| Diaz, MD | 1 |
| Vicente, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Trial Comparing Treatment With Melphalan+Prednisolon (MP) With Melphalan+Prednisolon+Thalidomide (MPT) for Previously Untreated Elderly Patients With Multiple Myeloma[NCT00934154] | Phase 3 | 122 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Pilot Study on the Efficacy of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive by Next Generation Flow[NCT03992170] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-12-31 | Recruiting | ||
| A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for[NCT05218603] | 100 participants (Anticipated) | Observational | 2021-11-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thalidomide and Opportunistic Infections
| Article | Year |
|---|---|
Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies.
Topics: Drug Therapy, Combination; Evidence-Based Medicine; Humans; Immunocompromised Host; Immunologic Fact | 2018 |
2 trials available for thalidomide and Opportunistic Infections
5 other studies available for thalidomide and Opportunistic Infections
| Article | Year |
|---|---|
Opportunistic virus infections in psoriasis patients: The safer alternative of apremilast in the COVID-19 era.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID | 2020 |
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Inci | 2011 |
Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma.
Topics: Angiogenesis Inhibitors; Female; Herpes Simplex; Herpes Zoster; Humans; Middle Aged; Multiple Myelom | 2002 |
Thalidomide in painful AIDS-associated proctitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Humans; Male; Opportunistic Infections; Proctitis; Thalid | 1992 |
Thalidomide in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Humans; Male; Mycobacterium avium-intracellulare Infectio | 1992 |